The effects of hormonal contraceptives on bone turnover markers and bone health

Clinical Endocrinology

Volumn 72, Issue 5, 2010, Pages 571-583

  Herrmann, Markus ^a   Seibel, Markus J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN; DESOGESTREL; DROSPIRENONE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; HYDROXYPROLINE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; OSTEOCALCIN;

ACNE; BIOCHEMISTRY; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CELL CYCLE REGULATION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CROSS-SECTIONAL STUDY; DRUG ACTIVITY; DRUG FORMULATION; FRACTURE; HAIR LOSS; HIRSUTISM; HORMONAL CONTRACEPTION; HORMONE ACTION; HUMAN; HYPERTRICHOSIS; LONGITUDINAL STUDY; MONOTHERAPY; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OVULATION INHIBITION; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTIN ONLY HORMONAL CONTRACEPTIVE; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGE FACTORS; BONE AND BONES; BONE DENSITY; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MIDDLE AGED; WOMEN'S HEALTH;

EID: 77950275718     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03688.x     Document Type: Review

References (89)

1. Practice Committee of the American Society for Reproductive Medicine (2006) Hormonal contraception: recent advances and controversies. Fertility and Sterility, 86, S229 S235.
2. Compston, J.E. (2001) Sex steroids and bone. Physiological Reviews, 81, 419 447.
3. Meier, C., Liu, P.Y., Handelsman, D.J. et al. (2005) Endocrine regulation of bone turnover in men. Clinical Endocrinology (Oxford), 63, 603 616.
4. Alexandre, C. (2005) Androgens and bone metabolism. Joint Bone Spine, 72, 202 206.
5. Martins, S.L., Curtis, K.M. Glasier, A.F. (2006) Combined hormonal contraception and bone health: a systematic review. Contraception, 73, 445 469.
6. Lippuner, K., Golder, M. Greiner, R. (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporosis International, 16, S8 S17.
7. Haussler, B., Gothe, H., Gol, D. et al. (2007) Epidemiology, treatment and costs of osteoporosis in Germany - the BoneEVA Study. Osteoporosis International, 18, 77 84.
8. Seibel, M.J. (2006) Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. The Clinical Biochemists. Reviews, 27, 123 138.
9. Seibel, M.J. (2003) Biochemical markers of bone remodeling. Endocrinology and Metabolism Clinics of North America, 32, 83 113.
10. Delmas, P.D., Eastell, R., Garnero, P. et al. (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis International, 11 (Suppl. 6 S2 S17.
11. Sitruk-Ware, R. (2006) New progestagens for contraceptive use. Human Reproduction Update, 12, 169 178.
12. Kiley, J. Hammond, C. (2007) Combined oral contraceptives: a comprehensive review. Clinical Obstetrics and Gynecology, 50, 868 877.
13. Ishida, Y., Ishida, Y. Heersche, J.N. (2002) Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis. Osteoporosis International, 13, 601 605.
14. Wiegratz, I. Kuhl, H. (2006) Metabolic and clinical effects of progestogens. European Journal of Contraception & Reproductive Health Care, 11, 153 161.
15. Benagiano, G. Primiero, F.M. (2003) Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Annals of the New York Academy of Sciences, 997, 163 173.
16. Benagiano, G., Primiero, F.M. Farris, M. (2004) Clinical profile of contraceptive progestins. European Journal of Contraception & Reproductive Health Care, 9, 182 193.
17. Speroff, L. Darney, P.D. (2005) Oral contraception. In : L. Speroff, P.D. Darney eds. A Clinical Guide for Contraception, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp. 11 62.
18. Seibel, M.J., Cosman, F., Shen, V. et al. (1993) Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 8, 881 889.
19. Huang, A.J., Ettinger, B., Vittinghoff, E. et al. (2007) Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women. Journal of Bone and Mineral Research, 22, 1791 1797.
20. Prince, R.L., Dick, I.M., Beilby, J. et al. (2007) A cohort study of the effect of endogenous estrogen on spine fracture risk and bone structure in elderly women and an assessment of its diagnostic usefulness. Bone, 41, 33 38.
21. Sillem, M., Parviz, M., Woitge, H.W. et al. (1999) Add-back medrogestone does not prevent bone loss in premenopausal women treated with goserelin. Experimental and Clinical Endocrinology and Diabetes, 107, 379 385.
22. Hassager, C., Colwell, A., Assiri, A.M. et al. (1992) Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clinical Endocrinology (Oxford), 37, 45 50.
23. Reginster, J.Y., Christiansen, C., Dequinze, B. et al. (1993) Effect of transdermal 17 beta-estradiol and oral conjugated equine estrogens on biochemical parameters of bone resorption in natural menopause. Calcified Tissue International, 53, 13 16.
24. Christiansen, C. Lindsay, R. (1990) Estrogens, bone loss and preservation. Osteoporosis International, 1, 7 13.
25. Mac, N.P. Loughrey, H.C. (1998) Progesterone receptor A and B isoform expression in human osteoblasts. Calcified Tissue International, 63, 39 46.
26. MacNamara, P., O'Shaughnessy, C., Manduca, P. et al. (1995) Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcified Tissue International, 57, 436 441.
27. Liang, M., Liao, E.Y., Xu, X. et al. (2003) Effects of progesterone and 18-methyl levonorgestrel on osteoblastic cells. Endocrine Research, 29, 483 501.
28. Wang, Q.P., Xie, H., Yuan, L.Q. et al. (2009) Effect of progesterone on apoptosis of murine MC3T3-E1 osteoblastic cells. Amino Acids, 36, 57 63.
29. Grosse, B., Kachkache, M., Le, M.V. et al. (2000) Membrane signalling and progesterone in female and male osteoblasts. I. Involvement of intracellular Ca(2 +), inositol trisphosphate, and diacylglycerol, but not cAMP. Journal of Cellular Biochemistry, 79, 334 345.
30. Wiren, K.M., Toombs, A.R., Semirale, A.A. et al. (2006) Osteoblast and osteocyte apoptosis associated with androgen action in bone: requirement of increased Bax/Bcl-2 ratio. Bone, 38, 637 651.
31. Wiren, K.M. (2005) Androgens and bone growth: it's location, location, location. Current Opinion in Pharmacology, 5, 626 632.
32. Takai, H., Nakayama, Y., Kim, D.S. et al. (2007) Androgen receptor stimulates bone sialoprotein (BSP) gene transcription via cAMP response element and activator protein 1/glucocorticoid response elements. Journal of Cellular Biochemistry, 102, 240 251.
33. Notini, A.J., McManus, J.F., Moore, A. et al. (2007) Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. Journal of Bone and Mineral Research, 22, 347 356.
34. Wiren, K.M., Zhang, X., Chang, C. et al. (1997) Transcriptional up-regulation of the human androgen receptor by androgen in bone cells. Endocrinology, 138, 2291 2300.
35. Zhou, H., Mak, W., Zheng, Y. et al. (2008) Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. Journal of Biological Chemistry, 283, 1936 1945.
36. Zhou, H., Mak, W., Kalak, R. et al. (2009) Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development, 136, 427 436.
37. Mazziotti, G., Angeli, A., Bilezikian, J.P. et al. (2006) Glucocorticoid-induced osteoporosis: an update. Trends in Endocrinology and Metabolism, 17, 144 149.
38. Canalis, E. (2005) Mechanisms of glucocorticoid action in bone. Current Osteoporosis Reports, 3, 98 102.
39. Canalis, E. (2003) Mechanisms of glucocorticoid-induced osteoporosis. Current Opinion in Rheumatology, 15, 454 457.
40. Alesci, S., De Martino, M.U., Ilias, I. et al. (2005) Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects. Neuroimmunomodulation, 12, 1 19.
41. Lin, Y., Dueker, S.R., Follett, J.R. et al. (2004) Quantitation of in vivo human folate metabolism. American Journal of Clinical Nutrition, 80, 680 691.
42. Seibel, M.J. (2005) Clinical use of markers of bone turnover in metastatic bone disease. Nature Clinical Practice. Oncology, 2, 504 517.
43. Chen, J.S., Cameron, I.D., Cumming, R.G. et al. (2006) Effect of age-related chronic immobility on markers of bone turnover. Journal of Bone and Mineral Research, 21, 324 331.
44. Seibel, M.J. (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. The Clinical Biochemists. Reviews, 26, 97 122.
45. Garnero, P., Sornay-Rendu, E. Delmas, P.D. (1995) Decreased bone turnover in oral contraceptive users. Bone, 16, 499 503.
46. de Papp, A.E., Bone, H.G., Caulfield, M.P. et al. (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone, 40, 1222 1230.
47. Ott, S.M., Scholes, D., LaCroix, A.Z. et al. (2001) Effects of contraceptive use on bone biochemical markers in young women. Journal of Clinical Endocrinology and Metabolism, 86, 179 185.
48. Gargano, V., Massaro, M., Morra, I. et al. (2008) Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception, 78, 10 15.
49. Weaver, C.M., Teegarden, D., Lyle, R.M. et al. (2001) Impact of exercise on bone health and contraindication of oral contraceptive use in young women. Medicine and Science in Sports and Exercise, 33, 873 880.
50. Herrmann, M. Herrmann, W. (2004) The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. Clinical Chemistry and Laboratory Medicine, 42, 1384 1389.
51. Rome, E., Ziegler, J., Secic, M. et al. (2004) Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. Journal of Pediatric and Adolescent Gynecology, 17, 373 377.
52. Polatti, F., Perotti, F., Filippa, N. et al. (1995) Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception, 51, 221 224.
53. Mais, V., Fruzzetti, F., Ajossa, S. et al. (1993) Bone metabolism in young women taking a monophasic pill containing 20 mcg ethinylestradiol: a prospective study. Contraception, 48, 445 452.
54. Paoletti, A.M., Orru, M., Lello, S. et al. (2004) Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. Contraception, 70, 293 298.
55. Grinspoon, S.K., Friedman, A.J., Miller, K.K. et al. (2003) Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. Journal of Clinical Endocrinology and Metabolism, 88, 3651 3656.
56. Vescovi, J.D., Vanheest, J.L. De Souza, M.J. (2008) Short-term response of bone turnover to low-dose oral contraceptives in exercising women with hypothalamic amenorrhea. Contraception, 77, 97 104.
57. Barad, D., Kooperberg, C., Wactawski-Wende, J. et al. (2005) Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. Fertility and Sterility, 84, 374 383.
58. Cooper, C., Hannaford, P., Croft, P. et al. (1993) Oral contraceptive pill use and fractures in women: a prospective study. Bone, 14, 41 45.
59. Vessey, M., Mant, J. Painter, R. (1998) Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception, 57, 231 235.
60. Vestergaard, P., Rejnmark, L. Mosekilde, L. (2008) Fracture risk in very young women using combined oral contraceptives. Contraception, 78, 358 364.
61. O' Neill, T.W., Silman, A.J., Naves, D.M. et al. (1997) Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. European Vertebral Osteoporosis Study Group. Osteoporosis International, 7, 72 78.
62. O' Neill, T.W., Marsden, D., Adams, J.E. et al. (1996) Risk factors, falls, and fracture of the distal forearm in Manchester, UK. Journal of Epidemiology and Community Health, 50, 288 292.
63. La, V.C., Tavani, A. Gallus, S. (1999) Oral contraceptives and risk of hip fractures. Lancet, 354, 335 336.
64. Mallmin, H., Ljunghall, S., Persson, I. et al. (1994) Risk factors for fractures of the distal forearm: a population-based case-control study. Osteoporosis International, 4, 298 304.
65. Pikkarainen, E., Lehtonen-Veromaa, M., Mottonen, T. et al. (2008) Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception, 78, 226 231.
66. Cromer, B.A., Stager, M., Bonny, A. et al. (2004) Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. Journal of Adolescent Health, 35, 434 441.
67. Cromer, B.A., Blair, J.M., Mahan, J.D. et al. (1996) A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. Journal of Pediatrics, 129, 671 676.
68. Lara-Torre, E., Edwards, C.P., Perlman, S. et al. (2004) Bone mineral density in adolescent females using depot medroxyprogesterone acetate. Journal of Pediatric and Adolescent Gynecology, 17, 17 21.
69. Cromer, B.A., Bonny, A.E., Stager, M. et al. (2008) Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertility and Sterility, 90, 2060 2067.
70. Nappi, C., Di Spiezio, S.A., Greco, E. et al. (2005) Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density. Obstetrics and Gynecology, 105, 53 60.
71. Nappi, C., Di Spiezio, S.A., Acunzo, G. et al. (2003) Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study. Contraception, 67, 355 359.
72. Reed, S.D., Scholes, D., LaCroix, A.Z. et al. (2003) Longitudinal changes in bone density in relation to oral contraceptive use. Contraception, 68, 177 182.
73. Berenson, A.B., Breitkopf, C.R., Grady, J.J. et al. (2004) Effects of hormonal contraception on bone mineral density after 24 months of use. Obstetrics and Gynecology, 103, 899 906.
74. Recker, R.R., Davies, K.M., Hinders, S.M. et al. (1992) Bone gain in young adult women. JAMA, 268, 2403 2408.
75. Collins, J. Crosignani, P.G. (2003) Hormonal contraception without estrogens. Human Reproduction Update, 9, 373 386.
76. Shaarawy, M., El- Mallah, S.Y., Seoudi, S. et al. (2006) Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. Contraception, 74, 297 302.
77. Walsh, J.S., Eastell, R. Peel, N.F. (2008) Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. Journal of Clinical Endocrinology and Metabolism, 93, 1317 1323.
78. VanderJagt, D.J., Sagay, A.S., Imade, G.E. et al. (2005) Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover. Contraception, 72, 212 216.
79. Naessen, T., Olsson, S.E. Gudmundson, J. (1995) Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception, 52, 35 39.
80. Berenson, A.B., Radecki, C.M., Grady, J.J. et al. (2001) A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstetrics and Gynecology, 98, 576 582.
81. Wanichsetakul, P., Kamudhamas, A., Watanaruangkovit, P. et al. (2002) Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception, 65, 407 410.
82. Cundy, T., Ames, R., Horne, A. et al. (2003) A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. Journal of Clinical Endocrinology and Metabolism, 88, 78 81.
83. Cundy, T., Cornish, J., Roberts, H. et al. (1998) Spinal bone density in women using depot medroxyprogesterone contraception. Obstetrics and Gynecology, 92, 569 573.
84. Cundy, T., Evans, M., Roberts, H. et al. (1991) Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ, 303, 13 16.
85. Clark, M.K., Sowers, M.R., Nichols, S. et al. (2004) Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertility and Sterility, 82, 1580 1586.
86. Kaunitz, A.M., Arias, R. McClung, M. (2008) Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception, 77, 67 76.
87. Seibel, M.J. (2008) The use of molecular markers of bone turnover in the management of patients with metastatic bone disease. Clinical Endocrinology (Oxford), 68, 839 849.
88. Grainge, M.J., Coupland, C.A., Cliffe, S.J. et al. (2001) Reproductive, menstrual and menopausal factors: which are associated with bone mineral density in early postmenopausal women? Osteoporosis International, 12, 777 787.
89. Fortney, J.A., Feldblum, P.J., Talmage, R.V. et al. (1994) Bone mineral density and history of oral contraceptive use. Journal of Reproductive Medicine, 39, 105 109.